Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Shane Foo"'
Autor:
Emmanuel C. Patin, Pablo Nenclares, Charleen Chan Wah Hak, Magnus T. Dillon, Anton Patrikeev, Martin McLaughlin, Lorna Grove, Shane Foo, Heba Soliman, Joao P. Barata, Joanna Marsden, Holly Baldock, Jim Gkantalis, Victoria Roulstone, Joan Kyula, Amy Burley, Lisa Hubbard, Malin Pedersen, Simon A. Smith, Eleanor Clancy-Thompson, Alan A. Melcher, Masahiro Ono, Antonio Rullan, Kevin J. Harrington
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract The combination of radiotherapy/chemoradiotherapy and immune checkpoint blockade can result in poor outcomes in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Here, we show that combining ATR inhibition (ATRi)
Externí odkaz:
https://doaj.org/article/e03ce8982c174566b0e3ce1d9a1fbd10
Autor:
Victoria Jennings, Alan Melcher, Fiona Errington-Mais, Victoria Roulstone, Kevin J Harrington, Galabina Bozhanova, Shane Foo, Martin McLaughlin, Malin Pedersen, John Bell, Pablo Nenclares, Joan Kyula, Lizzie Appleton, Edward Armstrong, Masahiro Ono, Matthew K L Chiu, Anton Patrikeev, Nitya Mohan, Julia Hoebart, Emmanuel Patin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Over the past decade, cancer immunotherapies have revolutionized the treatment of melanoma; however, responses vary across patient populations. Recently, baseline tumor size has been identified as an independent prognostic factor for overa
Externí odkaz:
https://doaj.org/article/2760efb5528c442eb6992610bc801ce3
Autor:
Victoria Jennings, Kevin Harrington, Hardev Pandha, Alan Melcher, Adel Samson, Fiona Errington-Mais, Victoria Roulstone, Eva Crespo-Rodriguez, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Martin McLaughlin, Malin Pedersen, Richard Vile, Joan Kyula, Jehanne Hassan, Lizzie Appleton, Charleen ML Chan Wah Hak, Gabby Baker, Edward Armstrong, Matthew Chiu, Masahiro Ono
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to i
Externí odkaz:
https://doaj.org/article/316204113b0e4019ac28423a26ae7cf2
Autor:
Khin Thway, Kevin J Harrington, Alan A Melcher, Eva Crespo-Rodriguez, Katharina Bergerhoff, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Harriet Whittock, Richard Buus, Syed Haider, Gareth Muirhead, Kate Newbold, Robert S Coffin, Richard G Vile, Dae Kim, Martin McLaughlin, Malin Pedersen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mu
Externí odkaz:
https://doaj.org/article/ad0aeec772af4e7bb8cf7fe2244c748e
Autor:
Erik Oliemuller, Richard Newman, Siu Man Tsang, Shane Foo, Gareth Muirhead, Farzana Noor, Syed Haider, Iskander Aurrekoetxea-Rodríguez, Maria dM Vivanco, Beatrice A Howard
Publikováno v:
eLife, Vol 9 (2020)
SOX11 is an embryonic mammary epithelial marker that is normally silenced prior to birth. High SOX11 levels in breast tumours are significantly associated with distant metastasis and poor outcome in breast cancer patients. Here, we show that SOX11 co
Externí odkaz:
https://doaj.org/article/ba0899cdda394041938c14f10c71925f
Autor:
Andrew R. Reynolds, Naveen S. Vasudev, Martin Gore, James Larkin, Paul D. Nathan, Thomas Powles, Caroline J. Springer, Natasha Preece, Peter B. Vermeulen, Sophia Frentzas, Jonathan C. Welti, Mark R. Nathan, Shane Foo, Elaine Wan, Victoria L. Bridgeman
Supplementary Figure 1 Growth kinetics for all 786-0 xenografts included in the analysis from Figure 1; Supplementary Figure 2 Details of the in vitro angiogenesis assay; Supplementary Figure 3 Isolation of a sunitinib-refractory sub-line (786-0-R) f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a34cdaeccfc1b318be4dda0463f1aa30
https://doi.org/10.1158/1535-7163.22504000.v1
https://doi.org/10.1158/1535-7163.22504000.v1
Autor:
Andrew R. Reynolds, Naveen S. Vasudev, Martin Gore, James Larkin, Paul D. Nathan, Thomas Powles, Caroline J. Springer, Natasha Preece, Peter B. Vermeulen, Sophia Frentzas, Jonathan C. Welti, Mark R. Nathan, Shane Foo, Elaine Wan, Victoria L. Bridgeman
Sunitinib and pazopanib are antiangiogenic tyrosine kinase inhibitors (TKI) used to treat metastatic renal cell carcinoma (RCC). However, the ability of these drugs to extend progression-free and overall survival in this patient population is limited
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d79ea775b636def7c095ac76ea888fd
https://doi.org/10.1158/1535-7163.c.6537586.v1
https://doi.org/10.1158/1535-7163.c.6537586.v1
Autor:
Kevin J. Harrington, Martin McLaughlin, Alan Melcher, Anguraj Sadanandam, Anna C. Wilkins, Krisha Desai, Elisa Fontana, Chanthirika Ragulan, Galabina Bozhanova, Shane Foo, Radhika R. Patel, James T.E. Paget, Henry G. Smith, Alex Pearson, Emmanuel C. Patin, Eva Crespo-Rodriguez, Harriet Whittock, Malin Pedersen, Katharina F. Bergerhoff, Magnus T. Dillon
Purpose:ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to sensitize to chemotherapy and radiotherapy preclinically. Limited data have been published about the effect of these drugs on the tumor microenvironment.Experimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4954af3c614c3181d2ace55e502316ce
https://doi.org/10.1158/1078-0432.c.6527228.v1
https://doi.org/10.1158/1078-0432.c.6527228.v1
Autor:
Kevin J. Harrington, Martin McLaughlin, Alan Melcher, Anguraj Sadanandam, Anna C. Wilkins, Krisha Desai, Elisa Fontana, Chanthirika Ragulan, Galabina Bozhanova, Shane Foo, Radhika R. Patel, James T.E. Paget, Henry G. Smith, Alex Pearson, Emmanuel C. Patin, Eva Crespo-Rodriguez, Harriet Whittock, Malin Pedersen, Katharina F. Bergerhoff, Magnus T. Dillon
Supplementary figures and tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e78d734f34504452c9609a08573d068
https://doi.org/10.1158/1078-0432.22469357
https://doi.org/10.1158/1078-0432.22469357
Autor:
Victoria Roulstone, Joan Kyula, James Wright, Lu Yu, Aida Barreiro Alonso, Miriam Melake, Jyoti Choudhary, Richard Elliott, Christopher J. Lord, David Mansfield, Nik Matthews, Ritika Chauhan, Victoria Jennings, Charleen Chan, Holly Baldock, Francesca Butera, Elizabeth Appleton, Pablo Nenclares, Malin Pederson, Shane Foo, Emmanuel C. Patin, Antonio Rullan, Tencho Tenev, Pascal Meier, Jacob Van Vloten, Richard Vile, Hardev Pandha, Alan Melcher, Martin McLaughlin, Kevin Harrington
Cytoplasmic pattern recognition receptors (PRRs) for double-stranded RNA (RIG-I/MDA5) are key mediators of anti-viral responses. PRR agonists, such as dsRNA oncolytic Reovirus type 3 Dearing (Rt3D), potently activate RNA sensors. We used an unbiased
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::191db321ec85e6140c0873bbc184f878
https://doi.org/10.1101/2022.09.28.508679
https://doi.org/10.1101/2022.09.28.508679